Ulcerative Colitis
Conditions
Interventions
Gold Standard:Endoscopic mucosal healing is referenced by the grading of inflammatory activity in colonic mucosa, which is evaluated by an expert panel based on endoscopic scoring. Histological remiss
Index test:The dual-modal endoscopic diagnostic model for artificial intelligence-assisted ulcerative colitis mucosal healing assessment
Sponsors
Zhujiang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who have been clinically diagnosed with ulcerative colitis (UC) based on laboratory tests, imaging studies, endoscopy, and histopathological examination, excluding infectious and other non-infectious colitis, and meeting the diagnostic criteria for UC in the "Consensus Opinions on the Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)"; 2. Patients in clinical remission assessed using the Partial Mayo Score (PMS) with a score less than 3 and no single item scoring more than 1, who have not required steroid maintenance for at least 6 months; 3. Patients who agree to the collection of gastrointestinal imaging data files and to undergo endoscopic multi-site biopsies; 4. Patients who have received regular treatment and been followed up regularly for more than 12 months; 5. Volunteers who agree to participate in this clinical trial and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Poor bowel preparation (such as the presence of large amounts of mucus, bubbles, food residue, feces, with a Boston score less than 6), making it impossible to distinguish normal structures; 2. Patients with gastrointestinal malignancies; 3. Alteration of intestinal anatomy after surgical procedures (such as colectomy); 4. Pregnant women; 5. Presence of any condition that may limit patient compliance or hinder data collection, such as dementia, severe mental disorders, or inability to express consent; 6. Other situations where the investigator deems it inappropriate for the patient to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic Accuracy ;Sensitivity ;Specificity;Positive predictive value, PPV ;Negative predictive value, NPV ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Recurrence Rate;Disease Recurrence Rate; | — |
Countries
China
Contacts
Public ContactWang Xinying
Zhujiang Hospital, Southern Medical University
Outcome results
None listed